RCS - Aptamer Group PLC - Investor Technical Webinar

AptamerAnnouncement

08/08/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250808:nRSH5063Ua&default-theme=true

RNS Number : 5063U  Aptamer Group PLC  08 August 2025

 

8 August 2025

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Investor Technical Webinar

 

Aptamer Group plc (AIM: APTA), the leading developer of next-generation
synthetic binders delivering innovation to the life science industry, is
pleased to announce that Dr David Bunka, Chief Scientific Officer, will host a
webinar to provide an update on the Company's progress within its technical
development programmes.

 

The webinar will be broadcast on Thursday, 14 August 2025, at 6:00 pm (BST)
and will offer a detailed review of the latest data and technical
developments, building on insights shared through recent regulatory
announcements.

 

The webinar is open to shareholders and other interested parties who can
register for the event by using the following link:
https://www.turnerpope.com/register/
(https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.turnerpope.com%2Fregister%2F&data=05%7C02%7CAndy.Thacker%40TurnerPope.com%7C74cbef2d20544af8670908ddcebea83f%7Cff82bd738fe84a38a86994e58a240e55%7C0%7C0%7C638894040445013905%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=y9RIsFRmGB2WO81s8INMwVIG1QvC1DXIaQob5PB8vfE%3D&reserved=0)

 

- Ends -

 

For further information, please contact:

 

 Aptamer Group plc                                               +44 (0) 1904 217 404 

 Dr Arron Tolley, Chief Executive Officer
 SPARK Advisory Partners Limited - Nominated Adviser             +44 (0) 20 3368 3550 

 Andrew Emmott / Jade Bayat 
 Turner Pope Investments (TPI) Limited - Broker                  +44 (0) 20 3657 0050 

 James Pope / Andrew Thacker 
 Northstar Communications Limited - Investor Relations           +44 (0) 113 730 3896

 Sarah Hollins

 

About Aptamer Group

 

Aptamer Group is a leading developer of next-generation synthetic binders
delivering innovation to the life sciences industry. The Group develops
Optimer® binders, advanced molecules that work like antibodies by attaching
to specific targets in the body. These binders are used in medicine,
diagnostic tests, and research tools, offering benefits like high stability,
reliable performance, and lower costs compared to traditional antibodies.

 

Aptamer operates a fee-for-service business in the US$210 billion market for
antibody alternatives, working with all top 10 global pharmaceutical
companies. It is also building valuable Optimer® assets with partners, aiming
for future licensing revenue.

 

Founded in 2008, the Group listed on the London Stock Exchange AIM market in
December 2021 and is headquartered in York, UK.

 

To register for news alerts by email go to
https://aptamergroup.com/investors/investor-news-email-alerts/
(https://aptamergroup.com/investors/investor-news-email-alerts/)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASSDEFWEISEDA